logo

For the Inventor, By the Inventor

Yokohama, Japan

Haruhiko Koseki

This inventor holds 4 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Kazusa Dna Research Institute Foundation, Riken Corporation. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haruhiko Koseki. Retrieved from https://idiyas.com/inventor/haruhiko-koseki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 50.0

 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Kanagawa, JP (2015)
  • Yokohama, JP (2009 - 2020)

Company Filing History:

goldMedal2 out of 11 
 
Kazusa Dna Research Institute Foundation
 patents
silverMedal2 out of 890 
 
Riken Corporation
 patents

Years Active: 2009-2020

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 10813950 - Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells (2020-10-27),
2. 8945922 - Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way (2015-02-03),
3. 7816132 - DNA encoding plexin polypeptides and kits thereof (2010-10-19),
4. 7482322 - Plexin family-like polypeptide, and uses thereof (2009-01-27),

Title: Haruhiko Koseki: Innovator in Immunotherapy

Introduction

Haruhiko Koseki is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of immunotherapy, particularly in the development of innovative treatments using NKT cells. With a total of 4 patents, Koseki's work is at the forefront of cancer and autoimmune disease research.

Latest Patents

Koseki's latest patents include groundbreaking inventions such as immunotherapy using allo-NKT cells and cells for immunotherapy where the alpha chain of the T-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. His inventions provide agents for immunocyte therapy, comprising NKT cells obtained by differentiating in vitro a cell with a rearranged TCR gene. These innovations are aimed at treating cancer, infections, allergic diseases, and autoimmune diseases.

Career Highlights

Throughout his career, Koseki has worked with notable organizations, including RIKEN Corporation and the Kazusa DNA Research Institute Foundation. His research has focused on generating mature NKT cells from reprogrammed somatic cells, contributing to advancements in immune cell therapy.

Collaborations

Koseki has collaborated with esteemed colleagues such as Hiroshi Watarai and Masaru Taniguchi. Their joint efforts have furthered the understanding and application of NKT cell therapies.

Conclusion

Haruhiko Koseki's innovative work in immunotherapy exemplifies the potential of NKT cells in treating various diseases. His contributions continue to influence the field and inspire future research in immunological therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…